AMAT vs MRK: Which Is the Better Buy?

Side-by-side comparison of Applied Materials, Inc. and Merck & Co., Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-20.
Applied Materials, Inc. Β· Technology
$406.91
-12.0% upside to fair value
Grade B- High Quality
VS
Merck & Co., Inc. Β· Healthcare
$114.27
+3.3% upside to fair value
Grade C High Quality
QuantHub Verdict
MRK has more upside to fair value (+3.3%). MRK trades at a lower forward P/E (22.4x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric AMAT MRK
Current Price $406.91 $114.27
Fair Value Estimate $358.00 $118.00
Upside to Fair Value -12.0% +3.3%
Market Cap $322.9B $282.2B
Forward P/E 30.3x 22.4x
EV / EBITDA 30.2x 13.5x
Price / Sales 10.2x 4.3x
Price / FCF 51.6x 20.2x
Revenue Growth YoY +11.0% +5.0%
Gross Margin 49.9% 81.9%
Operating Margin 31.9% 27.5%
Return on Equity 47.0% 5.6%
Dividend Yield 0.45% 2.91%
FCF Yield 1.94% 4.95%
Analyst Consensus Strong Buy Overweight
Investment Thesis
AMAT β€” Applied Materials, Inc.
Applied Materials is the world's leading semiconductor and display equipment company, and the May 14 Q2 fiscal 2026 print materially strengthened the operating story. Revenue grew 11 percent year over year to a record $7.91 billion, non-GAAP earnings per share of $2.86 beat consensus of $2.68, and management guided Q3 to a record $8.95 billion in revenue with non-GAAP earnings per share of $3.36 …
MRK β€” Merck & Co., Inc.
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Accumulation Zones
Metric AMAT MRK
Zone Low $268.50 $88.50
Zone High $304.30 $100.30
In Buy Zone? No No
← AMAT Research    MRK Research β†’    All Research